KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Current Assets (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Current Assets for 16 consecutive years, with $14.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets rose 19.33% year-over-year to $14.5 million, compared with a TTM value of $14.5 million through Sep 2025, up 19.33%, and an annual FY2024 reading of $12.3 million, up 3.93% over the prior year.
  • Current Assets was $14.5 million for Q3 2025 at TherapeuticsMD, up from $13.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $160.0 million in Q3 2021 and bottomed at $11.5 million in Q1 2024.
  • Average Current Assets over 5 years is $55.3 million, with a median of $17.1 million recorded in 2023.
  • The sharpest move saw Current Assets skyrocketed 30.65% in 2021, then plummeted 80.11% in 2023.
  • Year by year, Current Assets stood at $119.5 million in 2021, then crashed by 53.67% to $55.4 million in 2022, then crashed by 78.69% to $11.8 million in 2023, then rose by 3.93% to $12.3 million in 2024, then rose by 18.3% to $14.5 million in 2025.
  • Business Quant data shows Current Assets for TXMD at $14.5 million in Q3 2025, $13.5 million in Q2 2025, and $12.5 million in Q1 2025.